Tag Archives: Stephen Brozak

Celldex Receives a Buy from WBB Securities

WBB Securities analyst Stephen Brozak reiterated a Buy rating on Celldex (NASDAQ: CLDX) today and set a price target of $10. The company’s shares opened today at $2.90. According to TipRanks.com, Brozak is a 4-star analyst with an average return

WBB Securities Believes Corium (NASDAQ: CORI) Won’t Stop Here

In a report issued on July 7, Stephen Brozak from WBB Securities assigned a Buy rating to Corium (NASDAQ: CORI), with a price target of $13. The company’s shares opened today at $8.75, close to its 52-week high of $9.51.

WBB Securities Upgrades Cidara Therapeutics to Hold

In a report released yesterday, Stephen Brozak from WBB Securities upgraded Cidara Therapeutics (NASDAQ: CDTX) to Hold, with a price target of $7.25. The company’s shares closed yesterday at $7.10, close to its 52-week low of $6.65. According to TipRanks.com,

WBB Securities Maintains a Buy Rating on T2 Biosystems

In a report issued on February 1, Stephen Brozak from WBB Securities maintained a Buy rating on T2 Biosystems (NASDAQ: TTOO), with a price target of $12. The company’s shares closed last Friday at $5.58, close to its 52-week low

Analyst’s Rating Update Following Alcobra’s (ADHD) FDA’s Clinical Hold

Healthcare

The share prices of the emerging pharmaceutical company Alcobra Ltd (NASDAQ: ADHD) had been plummeting recently and is currently near its 52-week low. This massive fall of more than 50% in few short weeks was triggered when the FDA placed a

Analyst Upgrades Scynexis (SCYX) Based on Positive Drug Developments

Drug capsuls

WBB Securities analyst Steve Brozak issues a research report to investors today, with insights on Scynexis Inc (NASDAQ: SCYX) recent announcement of two successful Phase II trials for SCY-078 and their recent loan terms with Solar Capital (NASDAQ: SLRC). Brozak noted that with the